Relmada Therapeutics, Inc. RLMD

RLMD Company Overview

Relmada Therapeutics, Inc. is a U.S.-based clinical-stage biotechnology company focused on developing therapies for central nervous system (CNS) disorders and other diseases with significant unmet medical needs. The company primarily operates within the biopharmaceutical industry, with research and development efforts centered on neuropsychiatric and neurological conditions. Relmada’s business model is based on advancing proprietary drug candidates through clinical development and, if successful, commercialization or strategic partnering.

The company’s principal asset historically has been REL-1017 (esmethadone), an NMDA receptor channel blocker investigated for major depressive disorder (MDD) and other CNS indications. Relmada has also pursued programs involving modified-release formulations and novel therapeutics targeting pain and mood disorders. The company was founded in 2004 and evolved from a specialty pharmaceutical platform into a clinical-stage neuroscience-focused biotechnology company. Its positioning has emphasized differentiated CNS drug development, particularly therapies designed to address treatment-resistant or inadequately treated psychiatric conditions.